A5008360123- Pharmacological Effects and Toxicity Studies
- Ovarian function and disorders
- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Neurological Complications and Syndromes
- Pregnancy and Medication Impact
- Neuroendocrine Tumor Research Advances
- Renal Transplantation Outcomes and Treatments
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2024
Universidad Nacional Autónoma de México
2022
<title>Abstract</title> <bold>Context: </bold>Dopamine agonists (DA), mainly cabergoline, are the primary therapy for prolactinomas. Risks factors related with biochemical recurrence after DA withdrawal not completely understood. <bold>Objective: </bold>To assess hyperprolactinemia risk dopamine agonist (DA) in <bold>Design: </bold>Retrospective, comparative, observational cohort study. Survival, and multivariate regression analyses were performed to estimate remission (prolactin (PRL) 3-25...
To evaluate hypothalamic-pi- tuitary-gonadal (HPG) axis alterations at 1 and 12 months after kidney transplan- tation (KT) their association with in- sulin resistance.A retrospective clinical study was conducted in a tertiary care center transplantation recipients (KTRs) aged 18- 50 years primary disease stable renal graft function. LH, FSH, E2/T, HOMA-IR were assessed KT.Twenty-five KTRs included; 53% men, the mean age 30.6±7.7 years. BMI 22.3 (20.4-24.6) kg/m2, 36% had hypogonadism month...
Resumo Objetivo: Avaliar as alterações do eixo hipotálamo-hipófise-gonadal (HHG) em 1 e 12 meses após transplante renal (TR) sua associação com a resistência à insulina. Métodos: Foi realizado um estudo clínico retrospectivo centro de cuidados terciários receptores (RTR) idade entre 18-50 anos doença primária função enxerto estável. LH, FSH, E2/T HOMA-IR foram avaliados o TR. Resultados: incluídos 25 RTR; 53% eram homens média foi 30,6±7,7 anos. O IMC 22,3 (20,4-24,6) kg/m2 36% apresentaram...